The Manufacturers Life Insurance Company Sells 3,113 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

The Manufacturers Life Insurance Company lessened its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 2.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 113,364 shares of the company’s stock after selling 3,113 shares during the period. The Manufacturers Life Insurance Company owned about 0.05% of Hims & Hers Health worth $2,088,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of HIMS. DRW Securities LLC purchased a new position in Hims & Hers Health in the 3rd quarter worth approximately $2,017,000. Alpha DNA Investment Management LLC bought a new stake in Hims & Hers Health during the 3rd quarter valued at $552,000. Charles Schwab Investment Management Inc. boosted its position in Hims & Hers Health by 15.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock valued at $30,714,000 after buying an additional 218,566 shares during the period. Massachusetts Financial Services Co. MA purchased a new position in shares of Hims & Hers Health in the third quarter valued at about $2,395,000. Finally, Intech Investment Management LLC bought a new position in shares of Hims & Hers Health during the third quarter valued at about $1,064,000. Institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

HIMS has been the topic of several recent analyst reports. Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their price target for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Needham & Company LLC began coverage on Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price for the company. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. TD Cowen restated a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. Finally, Canaccord Genuity Group lifted their target price on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Hims & Hers Health presently has an average rating of “Hold” and an average price target of $21.43.

Hims & Hers Health Trading Up 8.3 %

Shares of NYSE:HIMS opened at $34.23 on Monday. The stock has a fifty day simple moving average of $23.54 and a two-hundred day simple moving average of $20.49. Hims & Hers Health, Inc. has a 12-month low of $8.09 and a 12-month high of $35.02. The stock has a market capitalization of $7.48 billion, a price-to-earnings ratio of 77.80 and a beta of 1.25.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Hims & Hers Health’s revenue was up 77.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.04) EPS. As a group, equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Activity at Hims & Hers Health

In related news, CEO Andrew Dudum sold 45,767 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $16.33, for a total value of $747,375.11. Following the sale, the chief executive officer now owns 67,015 shares in the company, valued at approximately $1,094,354.95. This trade represents a 40.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Michael Chi sold 2,054 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $33.56, for a total transaction of $68,932.24. Following the sale, the insider now owns 184,947 shares of the company’s stock, valued at approximately $6,206,821.32. This represents a 1.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 974,495 shares of company stock valued at $22,548,139 over the last 90 days. Corporate insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.